Repatha® at ESC 2019
Updated ESC/EAS dyslipidaemia guidelines: Lower is better
ESC Congress 2019 in Paris, France, saw the launch of updated guidelines for the management of dyslipidaemias
featuring lower LDL-C goals across CV risk categories and the endorsement of PCSK9 inhibitors in patients unable to
achieve LDL-C targets with maximally tolerated statin and ezetimibe, including patients hospitalised with acute coronary
EVOPACS study: Early start, early LDL-C reduction with Repatha® in ACS
Results of the EVOPACS study were presented at ESC 2019 and showed that:
- Repatha® given in the acute phase of ACS delivered a powerful 77% reduction in LDL-C from baseline, when added to
a high-intensity statin2
- By adding Repatha®, 9 out of 10 patients reached the more stringent 2019 ESC/EAS LDL-C target of <55 mg/dl2
€10K raised for the World Heart Federation
At the Amgen booth we raised awareness of The Alarming Truth About Cholesterol with activities including an interactive
quiz, a cycling challenge and our atherosclerosis colouring wall.
Amgen made a donation for each activity completed by delegates, raising an impressive €10,000 for the World Heart Federation.